vs
Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and FORRESTER RESEARCH, INC. (FORR). Click either name above to swap in a different company.
BridgeBio Pharma, Inc. is the larger business by last-quarter revenue ($154.2M vs $101.1M, roughly 1.5× FORRESTER RESEARCH, INC.). FORRESTER RESEARCH, INC. runs the higher net margin — -33.5% vs -126.2%, a 92.7% gap on every dollar of revenue. On growth, BridgeBio Pharma, Inc. posted the faster year-over-year revenue change (2521.2% vs -6.5%). FORRESTER RESEARCH, INC. produced more free cash flow last quarter ($-4.3M vs $-56.5M).
Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...
Forrester Research, Inc. is a research and advisory firm working in research, consulting and events. Forrester’s clients include large global business, technology and consumer enterprises. The firm is headquartered in Cambridge, MA.
BBIO vs FORR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $154.2M | $101.1M |
| Net Profit | $-194.6M | $-33.9M |
| Gross Margin | 94.7% | 56.7% |
| Operating Margin | -90.5% | -36.6% |
| Net Margin | -126.2% | -33.5% |
| Revenue YoY | 2521.2% | -6.5% |
| Net Profit YoY | 27.2% | -7941.4% |
| EPS (diluted) | $-1.00 | $-1.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $154.2M | $101.1M | ||
| Q3 25 | $120.7M | $94.3M | ||
| Q2 25 | $110.6M | $111.7M | ||
| Q1 25 | $116.6M | $89.9M | ||
| Q4 24 | — | $108.0M | ||
| Q3 24 | — | $102.5M | ||
| Q2 24 | — | $121.8M | ||
| Q1 24 | $211.1M | $100.1M |
| Q4 25 | $-194.6M | $-33.9M | ||
| Q3 25 | $-184.9M | $-2.1M | ||
| Q2 25 | $-183.8M | $3.9M | ||
| Q1 25 | $-169.6M | $-87.3M | ||
| Q4 24 | — | $432.0K | ||
| Q3 24 | — | $-5.8M | ||
| Q2 24 | — | $6.3M | ||
| Q1 24 | $-36.2M | $-6.7M |
| Q4 25 | 94.7% | 56.7% | ||
| Q3 25 | 94.6% | 60.0% | ||
| Q2 25 | 96.7% | 55.5% | ||
| Q1 25 | 97.7% | 55.9% | ||
| Q4 24 | — | 58.8% | ||
| Q3 24 | — | 60.5% | ||
| Q2 24 | — | 57.3% | ||
| Q1 24 | 99.7% | 54.9% |
| Q4 25 | -90.5% | -36.6% | ||
| Q3 25 | -120.3% | 4.7% | ||
| Q2 25 | -121.4% | 6.2% | ||
| Q1 25 | -89.5% | -97.5% | ||
| Q4 24 | — | -0.5% | ||
| Q3 24 | — | -0.7% | ||
| Q2 24 | — | 9.3% | ||
| Q1 24 | 0.2% | -9.3% |
| Q4 25 | -126.2% | -33.5% | ||
| Q3 25 | -153.2% | -2.3% | ||
| Q2 25 | -166.2% | 3.5% | ||
| Q1 25 | -145.4% | -97.1% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | -5.7% | ||
| Q2 24 | — | 5.2% | ||
| Q1 24 | -17.1% | -6.7% |
| Q4 25 | $-1.00 | $-1.75 | ||
| Q3 25 | $-0.95 | $-0.11 | ||
| Q2 25 | $-0.95 | $0.20 | ||
| Q1 25 | $-0.88 | $-4.62 | ||
| Q4 24 | — | $0.02 | ||
| Q3 24 | — | $-0.30 | ||
| Q2 24 | — | $0.33 | ||
| Q1 24 | $-0.20 | $-0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $570.1M | $63.3M |
| Total DebtLower is stronger | $2.0B | — |
| Stockholders' EquityBook value | $-2.1B | $126.5M |
| Total Assets | $936.0M | $404.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $570.1M | $63.3M | ||
| Q3 25 | $643.0M | $65.1M | ||
| Q2 25 | $756.9M | $67.8M | ||
| Q1 25 | $540.6M | $75.6M | ||
| Q4 24 | — | $56.1M | ||
| Q3 24 | — | $62.8M | ||
| Q2 24 | — | $58.9M | ||
| Q1 24 | $519.7M | $61.4M |
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-2.1B | $126.5M | ||
| Q3 25 | $-1.9B | $157.7M | ||
| Q2 25 | $-1.8B | $159.5M | ||
| Q1 25 | $-1.6B | $147.4M | ||
| Q4 24 | — | $229.5M | ||
| Q3 24 | — | $234.3M | ||
| Q2 24 | — | $237.1M | ||
| Q1 24 | $-1.0B | $230.9M |
| Q4 25 | $936.0M | $404.0M | ||
| Q3 25 | $998.3M | $414.2M | ||
| Q2 25 | $1.1B | $436.0M | ||
| Q1 25 | $881.6M | $439.8M | ||
| Q4 24 | — | $503.9M | ||
| Q3 24 | — | $505.3M | ||
| Q2 24 | — | $524.2M | ||
| Q1 24 | $849.3M | $555.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-56.4M | $-3.2M |
| Free Cash FlowOCF − Capex | $-56.5M | $-4.3M |
| FCF MarginFCF / Revenue | -36.6% | -4.2% |
| Capex IntensityCapex / Revenue | 0.0% | 1.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $18.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-56.4M | $-3.2M | ||
| Q3 25 | $-109.6M | $1.2M | ||
| Q2 25 | $-80.7M | $-3.6M | ||
| Q1 25 | $-199.2M | $26.7M | ||
| Q4 24 | — | $-1.8M | ||
| Q3 24 | — | $264.0K | ||
| Q2 24 | — | $-2.9M | ||
| Q1 24 | $-219.5M | $611.0K |
| Q4 25 | $-56.5M | $-4.3M | ||
| Q3 25 | $-110.0M | $524.0K | ||
| Q2 25 | $-81.3M | $-4.2M | ||
| Q1 25 | — | $26.1M | ||
| Q4 24 | — | $-2.5M | ||
| Q3 24 | — | $-223.0K | ||
| Q2 24 | — | $-3.7M | ||
| Q1 24 | $-220.2M | $-815.0K |
| Q4 25 | -36.6% | -4.2% | ||
| Q3 25 | -91.2% | 0.6% | ||
| Q2 25 | -73.5% | -3.8% | ||
| Q1 25 | — | 29.0% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | -0.2% | ||
| Q2 24 | — | -3.1% | ||
| Q1 24 | -104.3% | -0.8% |
| Q4 25 | 0.0% | 1.1% | ||
| Q3 25 | 0.4% | 0.7% | ||
| Q2 25 | 0.5% | 0.5% | ||
| Q1 25 | 0.0% | 0.7% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | 0.3% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.93× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -4.24× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.46× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BBIO
Segment breakdown not available.
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
